Fast-Acting Insulin Now Approved for Pump Use

FDA expands use of Fiasp (insulin aspart) to be given via insulin pump

(RxWiki News) A fast-acting insulin can now be administered via an insulin pump, according to the US Food and Drug Administration (FDA).

The insulin is found under the names Fiasp (brand) and insulin aspart (active ingredient). Currently, this medication is available as an injection to be injected either under the fatty layer of the skin or into the vein.

Now, the FDA has expanded the use of this medication so that it can be given via an insulin pump.

What makes this insulin different is how fast it gets into the bloodstream. In fact, according to the manufacturer, it enters the bloodstream in approximately 2.5 minutes.

Fiasp is similar to NovoLog but is formulated with other ingredients to increase how quickly it is absorbed in the blood. It's approved to treat both type 1 and type 2 diabetes.

Because this medication works to lower blood sugar, there is always a risk for the blood sugar to drop too low. That's why it's important to monitor your blood sugar as directed by your doctor. It is especially important to monitor your blood sugar if you're feeling under the weather, have been vomiting, have diarrhea or have changed your physical activity levels.

This medication may lead to dizziness or blurred vision. Do not drive or operate heavy machinery until you know how this medication affects you.

Fiasp is a product of Novo Nordisk.

Speak with your health care provider if you have any questions about diabetes or the available treatments.

Written by Anyssa Garza, PharmD, BCMAS